Syros Pharmaceuticals Stock Today
| SYRS Stock | USD 0.16 0 2.75% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Syros Pharmaceuticals is selling for under 0.1556 as of the 26th of February 2025; that is 2.75 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.16. Syros Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 2016 | Category Healthcare | Classification Health Care |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. The company has 26.83 M outstanding shares of which 723.2 K shares are at this time shorted by private and institutional investors with about 0.37 trading days to cover. More on Syros Pharmaceuticals
Moving against Syros Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Syros Stock Highlights
| President CEO | Conley Chee | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSyros Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Syros Pharmaceuticals' financial leverage. It provides some insight into what part of Syros Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Syros Pharmaceuticals (SYRS) is traded on NASDAQ Exchange in USA. It is located in 35 CambridgePark Drive, Cambridge, MA, United States, 02140 and employs 68 people. Syros Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.21 M. Syros Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.83 M outstanding shares of which 723.2 K shares are at this time shorted by private and institutional investors with about 0.37 trading days to cover.
Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Syros Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationSyros Pharmaceuticals shows a total of 26.83 Million outstanding shares. 30% of Syros Pharmaceuticals outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Syros Ownership Details
Syros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-12-31 | 81.5 K | |
| State Street Corp | 2024-12-31 | 69.4 K | |
| Jane Street Group Llc | 2024-12-31 | 52.9 K | |
| Two Sigma Investments Llc | 2024-12-31 | 48.9 K | |
| Ubs Group Ag | 2024-12-31 | 45 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 45 K | |
| Northern Trust Corp | 2024-12-31 | 40.8 K | |
| 1492 Capital Management, Llc | 2024-12-31 | 39.2 K | |
| Virtu Financial Llc | 2024-12-31 | 32.8 K | |
| Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 2.8 M | |
| Blackrock Inc | 2024-12-31 | 277.3 K |
Syros Pharmaceuticals Historical Income Statement
Syros Stock Against Markets
Syros Pharmaceuticals Corporate Management
| James MD | Founder | Profile | |
| Lisa Roberts | Vice Resources | Profile | |
| JD Esq | Chief Development | Profile | |
| Eric Olson | Chief Scientific Officer | Profile | |
| Jason Haas | Chief Officer | Profile |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.